Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3.

被引：0
|
作者：
Raje, Noopur S.
Leleu, Xavier P.
Lesokhin, Alexander M.
Mohty, Mohamad
Nooka, Ajay K.
Leip, Eric
Conte, Umberto
Viqueira, Andrea
Manier, Salomon
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Harvard Med Sch, Boston, MA USA
[2] CHU Poitiers, Hop Miletrie, Pole Reg Cancerol, Poitiers, France
[3] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, Div Hematol & Oncol, New York, NY USA
[4] Sorbonne Univ, Hop St Antoine, Paris, France
[5] INSERM, UMRs938, Paris, France
[6] Emory Univ Hosp, Winship Canc Inst, Atlanta, GA USA
[7] Pfizer Inc, Cambridge, MA USA
[8] Pfizer Inc, New York, NY USA
[9] Pfizer SLU, Madrid, Spain
[10] CHU Lille, Lille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8040
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple myeloma (RRMM): a subgroup analysis from MagnetisMM-3
    Raab, M. S.
    Haenel, M.
    Raje, N.
    Leleu, X.
    Lesokhin, A.
    Mohty, M.
    Nooka, A. K.
    Leip, E.
    Conte, U.
    Viqueira, A.
    Manier, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 80 - 81
  • [2] Efficacy and Safety of Elranatamab by Age and Frailty in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Subgroup Analysis From MagnetisMM-3
    Raje, Noopur
    Leleu, Xavier
    Lesokhin, Alexander
    Mohty, Mohamad
    Nooka, Ajay K.
    Leip, Eric
    Conte, Umberto
    Viqueira, Andrea
    Manier, Salomon
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S497 - S497
  • [3] A subgroup analysis from MagnetisMM-3: the efficacy and safety of elranatamab by age and frailty in patients with relapsed or refractory multiple myeloma
    Noopur, Raje
    Xavier, Leleu
    Alexander, Lesokhin M.
    Mohamed, Mohty
    Ajay, Nooka
    Eric, Leip
    Umberto, Conte
    Andrea, Vlqueira
    Saloman, Manier
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S17 - S18
  • [4] Efficacy and Safety of Elranatamab in Black Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Subgroup Analysis of the Magnetismm Studies
    Varshavsky-Yanovsky, Asya
    Jethava, Yogesh
    Stevens, Don A.
    Nooka, Ajay K.
    Stiff, Patrick J.
    Perez-Cruz, Isabel
    Leip, Eric
    Lesokhin, Alexander
    BLOOD, 2023, 142
  • [5] Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3
    Larson, Sarah Marie
    Bahlis, Nizar J.
    Maisel, Christopher
    Karlin, Lionel
    Yanovsky, Asya Varshavsky
    Leip, Eric
    Sullivan, Sharon T.
    Viqueira, Andrea
    Touzeau, Cyrille
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Efficacy and safety of elranatamab in Japanese patients with relapsed/refractory multiple myeloma (RRMM): a pooled analysis from the MagnetisMM studies
    Ishida, Tadao
    Yokoyama, Hisayuki
    Suzuki, Kenshi
    Ito, Satoshi
    Nagai, Yuya
    Handa, Hiroshi
    Ito, Shigeki
    Kamei, Yoichi
    Nakamura, Masatoshi
    Viqueira, Andrea
    White, Jane Liang
    Take, Kazumi
    Moribe, Toyoki
    Iida, Shinsuke
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S186 - S187
  • [7] Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma: Cohort a of MagnetisMM-3
    Shay, Gemma
    Bahlis, Nizar
    Tomasson, Michael H.
    Mohty, Mohamad
    Niesvizky, Ruben
    Nooka, Ajay
    Manier, Salomon
    Maisel, Christopher
    Jethava, Yogesh
    Martinez-Lopez, Joaquin
    Prince, H. Miles
    Arnulf, Bertrand
    Rodriguez-Otero, Paula
    Koehne, Guenther
    Touzeau, Cyrille
    Raje, Noopur
    Iida, Shinsuke
    Raab, Marc-Steffen
    Leip, Eric
    Sullivan, Sharon
    Conte, Umberto
    Viqueira, Andrea
    Lesokhin, Alexander
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 16 - 17
  • [8] Efficacy and safety of elranatamab monotherapy in patients with relapsed/refractory multiple myeloma: a post-hoc subgroup analysis from MagnetisMM-3 with modified eligibility criteria
    Raab, Marc
    Manier, Salomon
    Prince, H. Miles
    Nooka, Ajay
    Kaedbey, Rayan
    Hillengass, Jens
    Ishida, Tadao
    Sullivan, Sharon
    Conte, Umberto
    Leip, Eric
    Viqueira, Andrea
    Raje, Noopur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S207 - S208
  • [9] Elranatamab exposure-safety analysis in patients with relapsed/refractory multiple myeloma: analysis from MagnetisMM studies
    Soltantabar, Pooneh
    Irby, Donald
    Hibma, Jennifer
    Wang, Diane
    Williams, Jason
    Czibere, Akos
    Viqueira, Andrea
    Hickman, Anne
    Elmeliegy, Mohamed
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S211 - S212
  • [10] Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort
    Grosicki, Sebastian
    Mellqvist, Ulf-Henrik
    Pruchniewski, Lukasz
    Crafoord, Jacob
    Trudel, Suzanne
    Min, Chang-Ki
    White, Darrell
    Alegre, Adrian
    Hansson, Markus
    Ikeda, Takashi
    Sunami, Kazutaka
    Leip, Eric
    Kudla, Arthur
    Finn, Gregory
    Koh, Youngil
    BLOOD, 2022, 140 : 4407 - 4408
12345